Cell-free DNA in large B-cell lymphoma: MRD and beyond

Brian J Sworder; David M Kurtz

doi:10.1053/j.seminhematol.2023.06.004

Cell-free DNA in large B-cell lymphoma: MRD and beyond

Semin Hematol. 2023 Jul;60(3):142-149. doi: 10.1053/j.seminhematol.2023.06.004. Epub 2023 Jul 7.

Authors

Brian J Sworder¹, David M Kurtz²

Affiliations

¹ Division of Oncology, Department of Medicine, Stanford University, Stanford, CA.
² Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; Stanford Cancer Institute, Stanford University, Stanford, CA. Electronic address: dkurtz@stanford.edu.

PMID: 37474409
PMCID: PMC10528139 (available on 2024-07-07)
DOI: 10.1053/j.seminhematol.2023.06.004

Abstract

Large B-cell lymphomas (LBCLs) are a strikingly diverse set of diseases, including clinical, biological, and molecular heterogeneity. Despite a wealth of information resolving this heterogeneity in the research setting, applying molecular features routinely in the clinic remains challenging. The advent of circulating tumor DNA (ctDNA) liquid biopsies promises to unlock additional molecular information in the clinic, including mutational genotyping, molecular classification, and minimal residual disease detection. Here, we examine the technologies, applications, and studies exploring the utility of ctDNA in LBCLs.

Keywords: Cell-free DNA; Circulating tumor DNA; Liquid biopsy; Lymphoma; Minimal residual disease.

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Biomarkers, Tumor
Cell-Free Nucleic Acids*
Circulating Tumor DNA* / genetics
Humans
Lymphoma, B-Cell* / genetics
Neoplasm, Residual / diagnosis

Substances

Cell-Free Nucleic Acids
Biomarkers, Tumor
Circulating Tumor DNA

Grants and funding

K08 CA241076/CA/NCI NIH HHS/United States